STOCKWATCH
·
Biotechnology: Biological Products (No Diagnostic Substances)
Quarterly ResultMay 14, 2026, 04:08 PM

Pluri Reports Q3 Net Loss $6.17M; Going Concern Doubt Raised

AI Summary

Pluri Inc. reported a net loss of $6.17 million for the three months ended March 31, 2026, and $19.18 million for the nine-month period, with revenues declining year-over-year. The company's management has raised substantial doubt about its ability to continue as a going concern, citing less than three months of operating resources. Discussions are ongoing with the European Investment Bank regarding a potential restructuring of a €20 million loan, equivalent to $27.41 million, which is due on June 1, 2026.

Key Highlights

  • Management estimates resources for less than three months, raising substantial doubt about Pluri's ability to continue as a going concern.
  • Net loss for the nine months ended March 31, 2026, increased to $19.18 million from $15.48 million year-over-year.
  • Net loss for the three months ended March 31, 2026, was $6.17 million, a slight decrease from $6.34 million in the prior year period.
  • Revenues for the nine months ended March 31, 2026, decreased to $681,000 from $938,000 year-over-year.
  • Cash and cash equivalents decreased to $3.42 million as of March 31, 2026, from $5.90 million at June 30, 2025.
  • Total assets decreased to $26.06 million as of March 31, 2026, from $38.68 million at June 30, 2025.
  • Shareholders' deficit widened to $18.60 million as of March 31, 2026, from $6.84 million at June 30, 2025.
  • The EIB Loan of $27.41 million is due June 1, 2026, with discussions ongoing for a potential restructuring.
PLUR
Biotechnology: Biological Products (No Diagnostic Substances)
Pluri Inc.

Price Impact